The Louisiana Clinical Trial Competitiveness and Patient Access Act aims to enhance the state's ability to attract clinical trials by establishing a supportive framework for clinical research. The legislation outlines the responsibilities of the Louisiana Economic Development department, which includes coordinating and marketing clinical trial capabilities while ensuring that participation from research entities and sponsors is voluntary and nonexclusive. Key provisions include definitions related to clinical trials, the role of external institutional review boards (IRBs), and the sharing of information while maintaining confidentiality. The Act emphasizes patient choice and institutional authority, prohibiting exclusive provider designations for clinical projects and allowing the use of external IRBs to streamline the review process.

Additionally, the bill introduces specific requirements for covered clinical projects, stating that these will apply only to projects initiated after the Act's effective date. It clarifies that a lack of a preexisting master agreement does not prevent the use of an external IRB if a lawful study-specific reliance arrangement can be executed. The legislation also ensures that local institutional review processes do not duplicate ethical reviews or delay projects based on administrative convenience. Overall, the Act seeks to create a more efficient and collaborative environment for clinical trials in Louisiana while safeguarding the interests of all parties involved.